Gonadotropin-releasing hormone agonist triggering is effective, even at a low dose, for final oocyte maturation in ART cycles: Case series

Abstract

Objective: To investigate the efficacy of low-dose gonadotropin-releasing hormone (GnRH) agonist for final oocyte maturation in females un - dergoing assisted reproductive treatment (ART) cycles. Material and Methods: Nine females undergoing ovarian stimulation in a GnRH antagonist protocol who received triptorelin 0.1 mg to triggerfinal oocyte maturation were included. Treatment outcomes of these patients were compared with those of controls, matched for age and oo - cyte number (n=14), who received 0.2 mg triptorelin at the same time. The luteal phase was supported with vaginal micronized progesteroneand oral estradiol hemihydrate 2 mg twice daily. Results: The mean (±) numbers of retrieved, metaphase II, and fertilized oocytes were 15.66±7.82, 14±7.28, and 10.11±5.86, respectively.The implantation and clinical pregnancy rates were 46.1% and 71.4%, respectively. Of the pregnancies, 2 were live births, 1 was a preterm birth(twins), 2 are on-going, and 2 ended as miscarriages. No case of OHSS was encountered. On comparison of the results of these patients (freshcycles; n=7) with those of matched controls, there were no significant differences in terms of retrieved mature oocytes, implantation rates, orclinical pregnancy rates (p>0.05). Conclusion: These findings suggest that low-dose GnRH agonist triggering has similar efficacy as standard doses in terms of retrieved matureoocytes and clinical pregnancy rates in in vitro fertilization cycles. (J Turk Ger Gynecol Assoc 2015; 16: 35-40)